FMP
NASDAQ
2.01 USD
-0.01 (-0.498%)
Mr. George Magrath M.B.A., M.D., M.S.
Healthcare
Biotechnology
https://www.ocuphire.com
NASDAQ
Ocuphire Pharma, Inc., a clinical-stage ophthalmic biopharmaceutical company, focuses on developing and commercializing therapies for the treatment of refractive and retinal eye disorders. Its lead product candidate is Nyxol eye drops, a once-daily preservative-free eye drop formulation of phentolamine mesylate, which is in Phase III clinical trial for dim light or night vision disturbances; and Phase 2b clinical trial for pharmacologically induced mydriasis, as well as that has completed Phase 2 VEGA-1 trial for presbyopia. The company also develops APX3330, a twice-a-day oral tablet to target pathways relevant to retinal and choroidal vascular diseases, such as diabetic retinopathy and dia...
0001228627
US67577R1023
67577R102
37000 Grand River Avenue
248 681 9815
US
14
Nov 10, 2005
0001228627
NASDAQ
Biotechnology
Healthcare
67577R102
US67577R1023
US
2.01
0.29
200.62k
49.87M
-
1.85-6.6
0
-
-
-
-
-4.37
-
https://www.ocuphire.com
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load the chart at this time.
We are unable to load this data!
Financial Information
Financial Summary Real-Time Price
Financial Statements
Financial Quarter Statements
Ratios Analysis
Dupont Analysis
Free Cashflow
Operating Data
Balance Sheet Data
Financial Modelling
Discounted Cashflow Model
Discounted Cashflow Model Levered
Free Cashflow Build-Up
Terminal Value
Intrinsic Value
Weighted Average Cost of Capital
Market Information
Stock Value
It looks like there's no news available.